Dried Blood Spot Multiplexed Steroid Profiling Using Liquid Chromatography Tandem Mass Spectrometry in Korean Neonates

다국어 초록 (Multilingual Abstract)

Background: Screening for congenital adrenal hyperplasia (CAH) using immunoassays for 17α-hydroxyprogesterone generates many false-positive results. We developed and validated a liquid chromatography–tandem mass spectrometry (LC-MS/MS) assay for simultaneous quantification of nine steroid hormones in dried blood spot (DBS) samples, and established reference intervals for these hormones.
Methods: We examined our method for linearity, precision, accuracy, extraction recovery, and matrix effects and determined the reference intervals of cortisol, 17α-hydroxyproges-terone, 11-deoxycortisol, 21-deoxycortisol, androstenedione, corticosterone, 11-deoxycorticosterone, testosterone, and progesterone in 1,146 DBS samples (from 272 preterm and 874 full-term neonates). Immunoassay and LC-MS/MS methods were compared for 17α-hydroxyprogesterone. Fourteen additional samples were tested to validate the clinical applicability of the LC-MS/MS method.
Results: The linearity range was 2.8–828.0 nmol/L for cortisol and 0.9–40.0 nmol/L for the other steroids (R2>0.99). Intra-day and inter-day precision CVs were 2.52–12.26% and 3.53–17.12%, respectively. Accuracy was 80.81–99.94%, and extraction recovery and matrix effects were 88.0–125.4% and 61.7–74.2%, respectively. There was a negative bias, with higher values measured by immunoassay compared with LC-MS/MS (r=0.8104, P< 0.0001). The LC-MS/MS method was successfully applied to the analysis of nine steroids in DBS for screening and diagnosis of CAH using the 14 additional samples.
Conclusions: Our method enables highly sensitive and specific assessment of nine steroids from DBS and is a promising tool for clinical analysis of CAH.

참고문헌 (Reference)

1 Matuszewski BK, "Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS" 75 : 3019-3030, 2003

2 Seo JY, "Steroid profiling for congenital adrenal hyperplasia by tandem mass spectrometry as a second-tier test reduces follow-up burdens in a tertiary care hospital : a retrospective and prospective evaluation" 42 : 121-127, 2014

3 Rauh M, "Steroid measurement with LC-MS/MS in pediatric endocrinology" 301 : 272-281, 2009

4 CLSI, "Spectrometry for androgen and estrogen measurements in serum. CLSI guideline C57"

5 Magnisali P, "Simultaneous quantification of 17α-OH progesterone, 11-deoxycortisol, Δ4-androstenedione, cortisol and cortisone in newborn blood spots using liquid chromatography-tandem mass spectrometry" 879 : 1565-1572, 2011

6 Rossi C, "Serum steroid profiling for congenital adrenal hyperplasia using liquid chromatography-tandem mass spectrometry" 411 : 222-228, 2010

7 CLSI, "Screening by tandem mass spectrometry. CLSI guideline NBS04. 2nd ed"

8 Ministry of Food and Drug Safety, "Republic of Korea. Guideline on Bioanalytical Method Validation 2013;12"

9 Janzen N, "Rapid steroid hormone quantification for congenital adrenal hyperplasia(CAH)in dried blood spots using UPLC liquid chromatography-tandem mass spectrometry" 76 : 1437-1442, 2011

10 Hicks RA, "Precursor-to-product ratios reflect biochemical phenotype in congenital adrenal hyperplasia" 10 : 123-131, 2014

11 Janzen N, "Newborn screening for congenital adrenal hyperplasia : additional steroid profile using liquid chromatography-tandem mass spectrometry" 92 : 2581-2589, 2007

12 Centers for Disease Control and Prevention, "NSQAP: Newborn Screening Quality Assurance Program. Laboratory Quality Assurance and Standardization Programs"

13 Travers S, "Multiplexed steroid profiling of gluco-and mineralocorticoids pathways using a liquid chromatography tandem mass spectrometry method" 165 : 202-211, 2017

14 CLSI, "Measurement procedure comparison and bias estimation using patient samples. CLSI guideline EP09c. 3rd ed"

15 Lacey JM, "Improved specificity of newborn screening for congenital adrenal hyperplasia by second-tier steroid profiling using tandem mass spectrometry" 50 : 621-625, 2004

16 IUPAC, "IUPAC Compendium of Chemical Terminology (The “Gold Book”). version 2.3.3"

17 International Conference on Harmonisation (ICH), "ICH topic Q2 (R1) Validation of analytical procedures: text and methodology"

18 European Medicines Agency Committee for Medicinal Products for Human Use (CHMP), "Guideline on bioanalytical method validation"

19 Janzen N, "Fast and direct quantification of adrenal steroids by tandem mass spectrometry in serum and dried blood spots" 861 : 117-122, 2008

20 CLSI, "Evaluation of the linearity of quantitative measurement procedures: A statistical approach; approved guideline. CLSI document EP06A"

21 Dietzen DJ, "Dried blood spot reference intervals for steroids and amino acids in a neonatal cohort of the National Children’s Study" 62 : 1658-1667, 2016

22 김보람, "Dried Blood Spot Testing for Seven Steroids Using Liquid Chromatography-Tandem Mass Spectrometry With Reference Interval Determination in the Korean Population" 대한진단검사의학회 35 (35): 578-585, 2015

23 Boelen A, "Determination of a steroid profile in heel prick blood using LC-MS/MS" 8 : 375-384, 2016

24 Horowitz GL, "Defining, establishing, and verifying reference intervals in the clinical laboratory, approved guideline. EP28-A3. 3rd ed"

25 Monostori P, "Concurrent confirmation and differential diagnosis of congenital adrenal hyperplasia from dried blood spots : application of a second-tier LC-MS/MS assay in a cross-border cooperation for newborn screening" 84 : 311-318, 2015

26 U.S. Department of Health, "Bioanalytical method validation guidance for industry 2018"

27 Fiet J, "A liquid chromatography/tandem mass spectometry profile of 16 serum steroids, including 21-deoxycortisol and 21-deoxycorticosterone, for management of congenital adrenal hyperplasia" 1 : 186-201, 2017